- AI-screener
- Securities US
- Pfizer, Inc.

Pfizer, Inc.
$23.38
$0.23
0.99%
6 Jun 20:00
$20.92
$31.54
52 weeks low/high
Market sentiment
Section about market participants' moods: bulls holding long positions (“longs”) and bears holding short positions (“shorts”).
Overall assessment
weak bearish sentiment increases
2day with a yield of0.99%
Long
100.00%Short
0.00%Index | Bulls | Bears |
---|---|---|
Confidence | — | |
Support | — | |
Cash flows | — |
Momentum
Indicators for analyzing trends in the instrument. Based on them you can choose the optimal moment to open or close a position.
Return/MDD
-0.44Sentiment
BullishStart Date
05.20.2025Duration
17Yield
-0.72%Avg.Yield
-2.94%
Volatility
2.03%Max MDD
-1.65%Avg. MDD
-7.77%Min Price
RUB 23.04Max Price
RUB 23.61
Protective stop levels
S/L 5%RUB 22.18 | S/L 10%RUB 21.02 | S/L 15%RUB 19.85 | |
---|---|---|---|
Day | 1.16% | 0.00% | 0.00% |
Week | 25.90% | 2.04% | 0.03% |
Month | 58.18% | 25.79% | 8.09% |
Technical analysis
- Trend ClassFlat and Down
- Trend PowerStrong trend
- PatternSymmetrical triangle
- EMA-20Bullish reversal2025-05-23 the price crossed up the moving average line and getting closer to the MA, which means that the upside trend weakens.
- EMA-50Bearish reversal2025-05-01 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.
- EMA-100Bearish reversal2025-03-10 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.
- StochasticBullish weakeningThe stochastic indicator is in the upper part of the neutral territory and it falls. These factors indicate that the downside trend is confirmed. Last signal: main and signal line crossing.
- RSIBullish weakeningRSI indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: exit from the overbought zone.
- MACDBullishOscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: up-crossing the middle level.
- Candle pattern typeLong Leggedconsists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.Date of signal:
Prices and risks
Price
Change | Change by industry | Min. | Max. | Volume | |
---|---|---|---|---|---|
Yesterday | -3.74% | 2.64% | $23.25 | $23.58 | 547.90M |
Week | -4.31% | 3.10% | $23.06 | $23.62 | 4.05B |
Month | -1.38% | 0.45% | $21.97 | $23.70 | 18.36B |
3 Months | -15.91% | 0.82% | $20.92 | $27.24 | 56.54B |
6 Months | -12.61% | 16.34% | $20.92 | $27.57 | 100.55B |
Year | -21.38% | 0.64% | $20.92 | $31.54 | 187.78B |
3 years | -58.34% | 75.95% | $20.92 | $54.93 | 553.45B |
5 years | -37.51% | 100.06% | $20.92 | $61.71 | 1.10T |
All time | 9.09% | 81.24% | $11.62 | $61.71 | 1.06T |
Volatility
PFE | By industry | |
---|---|---|
Yesterday | 8.76% | 1.28% |
Week | 3.14% | 7.29% |
Month | 5.95% | 10.86% |
3 Months | 9.98% | 20.88% |
6 Months | 15.22% | 29.79% |
Year | 24.02% | 39.37% |
3 years | 42.09% | 85.40% |
5 years | 57.39% | 115.71% |
All time | — | — |
- Sortino
- -0.64
- Sharpe
- -0.85
- Sterling
- -0.66
- Liquidity index
- 7.47
- Alpha
- -0.00081
- Beta
- 0.53
AI Factors
Drivers of growth or decline are external factors, selected using AI, that can significantly affect the price of a company's shares in the future.
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$132.75B
Capitalization
5.69B
Shares outstanding
Health Care
Sector
Pharmaceuticals
Industry
US7170811035
ISIN
100
Lot size
Dr. Albert Bourla D.V.M., DVM, Ph.D.
CEO
Website
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.